Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for the Treatment of Unresectable Hepatocellular Carcinoma With Cirrhotic Portal Hypertension: A Multicenter, Simon Two-Stage, Single-Arm Study

NCT07350070 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07350070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07350070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for the Treatment of Unresectable Hepatocellular Carcinoma With Cirrhotic Portal Hypertension: A Multicenter, Simon Two-Stage, Single-Arm Study
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
June 30, 2028
Enrollment
78 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, liver cirrhosis, portal hypertension